Trial Profile
Study to Evaluate the Induction of HBV Virus Neutralizing Antibodies in Healthy Vaccine Naive Adults and Non-responders and in Patients Chronically Infected With HBV Using VVX001
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs VVX 001 (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Viravaxx
- 30 Jan 2024 According to a Viravaxx medial release , the final report(n=64) of the phase 2 study VVX001-CS001 confirming the preliminary analysis performed earlier, has been published.
- 30 Jan 2024 According to a Viravaxx medial release , Primary endpoint (PreS specific IgG antibodies) has been met.
- 26 Jun 2022 Results presented at The International Liver Congress 2022